This will be the seventh Phase II trial for 427 ("Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer") .
Based on some of the posts from this very helpful message board (summer, kuvaz, sssamsa, box) and the company's own releases, I know we're in for a wait until 2014. But, it surely seems a good sign that they have enough confidence in 427 to launch so many trials. Also, if indeed the recent selloff was Fidelity (and who knows why, could be unrelated to anything with this particular stock) it seems we should be on a path upward now in terms of pps. What are others' thoughts?
I'm looking forward to ASCO and staying with this one for the long haul.
News cycle is in 2014 but as others have commented we should see a run starting 2H/13 as we move closer to these transformation trial events. I expect a major move in PPS and want to be positioned to take capital gains on my trading shares not ordinary income.